Volume 10, Number 2Review ArticlesManaging Bone Loss and Bone Metastases in Prostate Cancer Patients: A Focus on Bisphosphonate TherapyTreatment UpdateRon S IsraeliAndrogen deprivation therapy (ADT) and bone metastases are the most important risk factors for developing skeletal complications (eg, bone loss, pathologic fractures) in prostate cancer (PC) patients with locally advanced and metastatic disease. Bisphosphonates, which inhibit excessive osteoclast activity caused by ADT and bone metastases, have proven to be safe and effective in preventing skeletal complications and presently are the standard of care in patients with metastatic disease. Bisphosphonates should be considered for use in all PC patients with locally advanced disease initiating ADT for an intended duration of at least 1 year, especially those with a low baseline bone mineral density. [Rev Urol. 2008;10(2):99-110]Prostate cancerAndrogen deprivation therapySkeletal-related eventsBone metastasisBone lossBisphosphonates
Volume 16, Number 1Review ArticlesEmerging Therapeutic for the Treatment of Skeletal-related Events Associated With Metastatic Castrate-resistant Prostate CancerCME-certified ArticlePaul R SieberProstate cancer is the most prevalent cancer in US and European men and the second leading cause of cancer death in those populations. It is somewhat unique in that nearly all patients who succumb to the disease will ultimately develop bone metastasis. Morbidity from bone metastasis—referred to as skeletal-related events, which include fractures, cord compression, radiation to bone, and surgery to bone—leads to significant costs and impaired quality of life. This article reviews three agents and the roles they play in the ever-changing armamentarium of treatments for metastatic castrate-resistant prostate cancer (mCRPC). The potential benefits of these agents are discussed, as well as the continuing use of these agents and their earlier introduction in the patient with progressive mCRPC with bone metastasis. [Rev Urol. 2014;16(1):10-20 doi: 10.3909/riu0609] © 2014 MedReviews®, LLCMetastatic castrate-resistant prostate cancerSkeletal-related eventsBone metastasisZoledronic acidDenosumabRadium Ra 223 dichloride